Ewa Hellström-Lindahl1, Angelika Danielsson2,3, Fredrik Ponten2, Paul Czernichow4, Olle Korsgren2, Lars Johansson5, Olof Eriksson6. 1. Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University, 751 83, Uppsala, Sweden. 2. Department of Immunology, Genetics and Pathology, Uppsala University, 751 83, Uppsala, Sweden. 3. Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, 751 85, Uppsala, Sweden. 4. Endocells, 216 BD Saint Germain, 75007, Paris, France. 5. Department of Radiology, Oncology and Radiation Sciences, Uppsala University, 751 83, Uppsala, Sweden. 6. Department of Medicinal Chemistry, Preclinical PET Platform, Uppsala University, 751 83, Uppsala, Sweden. olof.eriksson@pet.medchem.uu.se.
Abstract
AIMS: To address questions regarding onset and progression of types 1 and 2 diabetes (T1D/T2D), surrogate imaging biomarkers for beta cell function and mass are needed. Here, we assess the potential of GPR44 as a surrogate marker for beta cells, in a direct comparison with clinically used biomarker VMAT2. METHODS: GPR44 surface availability was assessed by flow cytometry of human beta cells. RNA transcription levels in different pancreas compartments were evaluated. The density of GPR44 receptor in endocrine and exocrine tissues was assessed by the radiolabeled GPR44 ligand [(3)H]AZD 3825. A direct comparison with the established beta cell marker VMAT2 was performed by radiolabeled [(3)H]DTBZ. RESULTS: GPR44 was available on the cell surface, and pancreatic RNA levels were restricted to the islets of Langerhans. [(3)H]AZD 3825 had nanomolar affinity for GPR44 in human islets and EndoC-βH1 beta cells, and the specific binding to human beta cells was close to 50 times higher than in exocrine preparations. The endocrine-to-exocrine binding ratio was approximately 10 times higher for [(3)H]AZD 3825 than for [(3)H]DTBZ. CONCLUSION: GPR44 is a highly beta cell-specific target, which potentially offers improved imaging contrast between the human beta cell and the exocrine pancreas.
AIMS: To address questions regarding onset and progression of types 1 and 2 diabetes (T1D/T2D), surrogate imaging biomarkers for beta cell function and mass are needed. Here, we assess the potential of GPR44 as a surrogate marker for beta cells, in a direct comparison with clinically used biomarker VMAT2. METHODS:GPR44 surface availability was assessed by flow cytometry of human beta cells. RNA transcription levels in different pancreas compartments were evaluated. The density of GPR44 receptor in endocrine and exocrine tissues was assessed by the radiolabeled GPR44 ligand [(3)H]AZD 3825. A direct comparison with the established beta cell marker VMAT2 was performed by radiolabeled [(3)H]DTBZ. RESULTS:GPR44 was available on the cell surface, and pancreatic RNA levels were restricted to the islets of Langerhans. [(3)H]AZD 3825 had nanomolar affinity for GPR44 in human islets and EndoC-βH1 beta cells, and the specific binding to human beta cells was close to 50 times higher than in exocrine preparations. The endocrine-to-exocrine binding ratio was approximately 10 times higher for [(3)H]AZD 3825 than for [(3)H]DTBZ. CONCLUSION:GPR44 is a highly beta cell-specific target, which potentially offers improved imaging contrast between the human beta cell and the exocrine pancreas.
Authors: Timothy M Horton; Paul A Allegretti; Sooyeon Lee; Hannah P Moeller; Mark Smith; Justin P Annes Journal: Cell Chem Biol Date: 2018-12-06 Impact factor: 8.116
Authors: Pierre Cheung; Bo Zhang; Emmi Puuvuori; Sergio Estrada; Mohammad A Amin; Sofie Ye; Olle Korsgren; Luke R Odell; Jonas Eriksson; Olof Eriksson Journal: Biomedicines Date: 2021-04-16
Authors: Stanko Skrtic; Björn Tyrberg; Malin Broberg; Hans Ericsson; Volker Schnecke; Magnus Kjaer; Marcus Hompesch; Eva-Marie Andersson; Erik Ryberg; Alexander Aivazidis; Charlotte Wennberg Huldt; Lars Löfgren; Linda Morrow; Joanna Parkinson; Tina Rydén-Bergsten; Elaine Watkins; Maria Sörhede Winzell Journal: PLoS One Date: 2018-12-17 Impact factor: 3.240
Authors: Harpreet K Sandhu; Joshua C Neuman; Michael D Schaid; Sarah E Davis; Kelsey M Connors; Romith Challa; Erin Guthery; Rachel J Fenske; Chinmai Patibandla; Richard M Breyer; Michelle E Kimple Journal: Pharmacol Res Perspect Date: 2021-04